

Company profile

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions and focus on single-use technologies are supporting biopharma companies around the world to develop and produce drugs safely, timely and economically. Head-quartered in Aubagne, France, Sartorius Stedim Biotech employs around 10,250 people in more than 30 countries.

Investment Highlights

- 1. Focus on the high-growth biopharma market
- 2. Broad and differentiating product offering
- 3. Strong global presence
- 4. High share of recurring business; significant market entry barriers
- 5. Proven track record with alliances and acquisitions;
- 6. High continuity with respect to customer base, employees and management

Key Figures


in millions of € unless otherwise specified

	9M 2026	Δ in %	9M 2025	FY 2025	FY 2024	FY 2023
Sales revenue (% Δ in const. fx)	2,289.2	+7.8 ¹ 6.5	2,195.3	2,967.5	2,780.0	2,775.5
Underlying EBITDA ²	716.0	+4.8	683.1	913.7	779.0	785.4
Underlying EBITDA margin ² in %	31.3	+0.2pp	31.1	30.8	28.0	28.3
Underlying net profit after non-controlling interest ³	349.6	+9.4	319.5	427.7	337.5	385.9
Underlying Earnings per share ³ in €	3.59	+9.4	3.28	4.40	3.49	4.19
Equity ratio ⁴ in %	54.6	+2.9pp	51.7	51.7	48.7	34.6
Ratio of net debt to underlying EBITDA ^{2,5}	2.26	-	2.52	2.38	2.81	4.46


1 Operational sales growth before customer compensation for tariff surcharges.
2 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items.
3 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.
4 Equity in relation to the balance sheet total.
5 Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period.

Figures are not audited or reviewed.

Sales and Earnings Development



Sales Revenue by Region 2025



Guidance for fiscal year 2026 confirmed and partially refined

Sales revenue growth ¹	~6% to ~10%
Underlying EBITDA margin	slightly > 31%

Where we expect to land within the range

Operational performance ²	around the midpoint
incl. customer compensation refund application of €35m; €8.5m still outstanding	lower half of the range

Other KPIs

Capex ratio	~13% (prev.: ~13.3%)
Net debt / underlying EBITDA	slightly >2x

Due to the continued high dynamics and volatility across the life science industry, the forecast remains subject to greater uncertainty, which is reflected in the current guidance range. Potential further changes in U.S. tariffs are not included.

1 In constant currencies. 2 Operational sales growth before customer compensation for tariff surcharges, in constant currencies.

Strategy

- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers’ production processes
- Global leading positions in key technology platforms; e.g. process filtration, fluid management, fermentation and membrane chromatography
- One of the widest portfolios in the industry with a clear focus on single-use technologies such as filters, bags and cell culture media
- Regionally focused on gaining market share in North America and leveraging our strong market growth in Asia
- Continuous expansion through complementary acquisitions and alliances


Facts about the Share

Ticker symbol: DIM
Ticker symbol Bloomberg: DIM:FP
Ticker symbol Reuters: STDM.P
ISIN: FR0013154002
Liquidity provider: Kepler Cheuvreux
Stock exchange: Euronext Paris
Market segment: Local Securities – Compartement A (Large Caps)
Indexes:

- SBF 120
- CAC Next 20
- CAC Large 60
- CAC HEALTH CARE
- STOXX Europe 600
- MSCI France


Sartorius Stedim Biotech Share (indexed)

October 1, 2025, to September 30, 2026




Shareholder Structure

September 30, 2026



Underlying Earnings per Share¹ in €



1 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.

Financial calendar

February 23, 2027
Full-year figures 2026 and 2026 Annual Report

April 13, 2027
Annual Shareholders Meeting

Disclaimer

This fact sheet contains statements concerning the future performance of the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbour risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.

Contact

Sven Köpsel
Head of Corporate Communication & IR
Tel.: +49.551.308.9429
Email: sven.koepsel@sartorius.com

Petra Müller
Head of Investor Relations
Tel.: +49.551.308.6035
Email: petra.mueller2@sartorius.com